Inhibikase Therapeutics, Inc. (IKT) research
Inhibikase Therapeutics, Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $2.15
- As of
Inhibikase Therapeutics, Inc. (IKT): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-08.
As of . Source: SEC EDGAR filings for IKT. Method and limitations.
Share the IKT intelligence card
See IKT live in the terminal
Track IKT's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live IKT terminal, freeActive signals for IKT
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +112% to IKT (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +112% to IKT (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +112% to IKT (2026Q2)
- highCONSENSUS_BUY
4 tracked funds increased IKT this 2026Q1 - institutional consensus
- mediumNEW_POSITION
Point72 Asset Management, L.P. new position in IKT
FREE, NO ACCOUNT
Every signal on IKT, as it fires
You are seeing 5 of 11 signals recorded on IKT since 2026-05-17.
The five above landed across 3 days. The other 6 were recorded on 1 other days. 7 of the 11 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in IKT (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 45719W205 · 2026Q2 | $8.2M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 45719W205 · 2026Q2 | $1.6M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 45719W205 · 2026Q2 | $151K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, IKT
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
IKT against its peers
IKT's return on equity of -27.9% ranks in the 55th percentile of 20 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-05-31.
| Metric | IKT | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 6.6M | n/a | 17 |
| Operating margin | n/a | -623.6% | n/a | 13 |
| Net margin | n/a | -358.1% | n/a | 14 |
| Return on equity | -27.9% | -33.6% | 55 | 20 |
Peers (23): VNDA, IFRX, QTTB, FATE, ABEO, SABS, ZNTL, UPB, SION, IMRX, CYDY, EYPT, STRO, IPSC, GLSI, CMPX, PALI, ANIK, LXEO, EVMN, NWBO, EBS, LYEL. Left out: VCRE (no annual filing), CUVL (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-05-31. Every figure is one full fiscal year read from one annual filing (IKT: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more IKT signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to IKTand get the insider, 13F, options, and confluence read in one view.